Skip to main content

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Record Order, Eyes Strong Commercial Traction for UltraShear Nanoemulsions Technology Platform

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, today announced entrance into an exclusive distribution agreement for the People’s Republic of China with PRS International Trade (Shanghai) Co., Ltd. Reflecting confidence in PBIO’s long investment in developing worldwide market support for the company’s Pressure Cycling Technology (“PCT”) platform, PRS International prepaid for the entire purchase of 16 Barocycler EXT units for a total of nearly $600,000, while committing to purchase additional units and related consumables before the end of 2023. “We have been focusing the majority of our efforts on the launch of our revolutionary UltraShear nanoemulsions processing platform, which we expect will lead to ramping revenue in 2023,” said Richard T. Schumacher, PBI’s president and CEO. “Additionally, our long-term investment in building broad-based market support for our line of pressure-based instruments continues to pay off with growing penetration and adoption for our initial high-pressure technology platforms and application areas. Our commitment to supporting this key area of our business remains unwavering. We are honored and humbled by the large, prepaid order from PRS International, and we are delighted to be in a position to reinvest our strengthening technical and financial foundation in support of our next generation UltraShear nanoemulsions technology platform that we believe will be manifesting strong commercial traction starting in this quarter.”

To view the full press release, visit https://ibn.fm/sZz0q

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Pressure BioSciences’ primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) patented technology from BaroFold Inc. (the BaroFold technology) that allows entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based UltraShear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.